Clinical trials: Cerebrovascular Diseases
Spontaneous Subarachnoid Hemorrhage
A New Minimal-invasive Brain Tissue Probe Applying Near Infrared Spectroscopy
To assess the feasibility of a new brain tissue probe for multi-parameter neuromonitoring (NeMo Probe) and the accuracy of measurement values.
- Trial name
- NCT01801306
- Testing
- NeMo Probe
- Where
- Germany
- Volunteers
- 3 people
- Sponsor
- NeMoDevices AG
Giant Cell Arteritis
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
Sirukumab is a fully human anti-interleukin-6 (IL-6) immunoglobulin G1-kappa with a high affinity and specificity for binding to the human IL-6 molecule that may have therapeutic benefit in the treatment of giant cell arteritis…
- Trial name
- NCT02531633
- Testing
- Sirukumab, Prednisone
- Where
- 63 sites in United States, Australia and 11 more
- Volunteers
- 161 people
- Sponsor
- GlaxoSmithKline
Cerebral Aneurysm
Surpass Flow Diverter for Intracranial Aneurysms: SURMOUNT Registry Data Collection
The purpose of this observational post-marketing registry will be to collect and analyze safety, effectiveness, and quality of life outcomes, during and after treatment with the Surpass Flow Diverter.
- Trial name
- NCT02281721
- Testing
- Surpass Flow Diverter(s)
- Where
- 19 sites in Belgium, Finland and 7 more
- Volunteers
- 150 people
- Sponsor
- Stryker Neurovascular
Coronary Artery Bypass Graft Surgery, Myocardial Ischemia
MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery)
The purpose of this study is to determine whether MC-1 is effective and safe in reducing cardiovascular and neurological events in patients undergoing high-risk coronary artery bypass surgery
- Conditions
- Coronary Artery Bypass Graft Surgery, Myocardial Ischemia, Reperfusion Injury, Myocardial Revascularization
- Trial name
- NCT00157716
- Testing
- (MC-1) Pyridoxal-5'-phosphate
- Where
- 2 sites in United States, Canada
- Volunteers
- 900 people
- Sponsor
- Medicure
Fabry Disease
A Study of Patients With Fabry Disease (US Specific)
This is an observational study to evaluate the effects of treatment on long-term effectiveness, safety, and health-related quality of life (HRQOL) in patients with Fabry disease, with a main focus on migalastat.
- Trial name
- NCT06906367
- Testing
- migalastat HCl, ERT
- Where
- 8 sites in United States
- Volunteers
- 450 people
- Sponsor
- Amicus Therapeutics
Acute Ischemic Stroke
The Vesalio NeVa Stent Retriever Study for Treatment of Large Vessel Occlusion Strokes
A prospective, open label, single-arm 90-day study designed to assess the safety, performance and efficacy of thrombus removal in subjects presenting with acute ischemic stroke with the NeVa stent retrievers.
- Trial name
- NCT03927001
- Testing
- NeVa Stent Retrievers
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- Vesalio
Fabry Disease
Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study
Study to evaluate the long-term safety, tolerability, and pharmacodynamics (PD) of migalastat hydrochloride (HCl) (migalastat) in participants with Fabry disease
- Trial name
- NCT00526071
- Testing
- migalastat HCl
- Where
- 8 sites in United States, Australia and 3 more
- Volunteers
- 23 people
- Sponsor
- Amicus Therapeutics
Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid
Phase Ib Study of SC Milatuzumab in SLE
Milatuzumab will be given subcutaneously at different dose levels once (depending on the dose level) for 4 weeks to determine if milatuzumab helps to control lupus (SLE).
- Conditions
- Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic, Lupus Vasculitis, Central Nervous System
- Trial name
- NCT01845740
- Testing
- milatuzumab
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Gilead Sciences
Aneurysm, Intracranial
Evaluation of Safety and Effectiveness of Stryker Surpass Evolve™ Flow Diverter System
The primary objective of this study is to evaluate the safety and effectiveness of the Surpass™ Evolve Flow Diverter System in the treatment of unruptured, wide-neck intracranial aneurysms measuring ≤ 12 mm and located on the ICA…
- Trial name
- EVOLVE (NCT04195568)
- Testing
- Surpass Evolve Flow Diverter System
- Where
- 37 sites in United States, Australia and 1 more
- Volunteers
- 248 people
- Sponsor
- Stryker Neurovascular
Intracranial Aneurysm
Safety and Efficacy Analysis of FRED™/FRED™Jr Embolic Device in Aneurysm Treatment
A prospective, multicenter, observational evaluation of the safety and efficacy of the FRED® device in the treatment of intracranial aneurysms
- Trial name
- NCT03423290
- Testing
- FRED and FRED Jr
- Where
- 7 sites in United Kingdom
- Volunteers
- 61 people
- Sponsor
- Microvention-Terumo, Inc.
Intracerebral Hemorrhage
A Study to Evaluate the Safety, Tolerability and the Effects of Ixodes Ricinus-Contact Phase Inhibitor (Ir-CPI) in Adult Patients With Spontaneous Intracerebral Haemorrhage
The purpose of the study is to provide a first assessment of safety, tolerability and efficacy of Ir-CPI, administered on top of standard-of-care, on secondary brain injury in patients with spontaneous intracerebral haemorrhage.
- Trial name
- BIRCH (NCT05970224)
- Testing
- Ir-CPI
- Where
- 8 sites in Belgium
- Volunteers
- 23 people
- Sponsor
- Bioxodes S.A.
Intracranial Saccular Aneurysm, Either Rupture or Unruptured, Wide Neck Aneurysm
Solitaire Aneurysm Remodeling Registry
The objective of the registry is to evaluate the effectiveness and performance of the Solitaire Neurovascular Remodeling Device when used with embolic coils in the treatment of intracranial aneurysms.
- Trial name
- NCT04905303
- Where
- France
- Sponsor
- Medtronic Neurovascular Clinical Affairs
Carotid Stenosis, Carotid Artery Diseases
The ENROUTE Transcarotid Neuroprotection System (ENROUTE Transcarotid NPS) DW-MRI Study
The goal of this study is to evaluate the incidence of post procedure DW-MRI lesions (relative to baseline) and debris captured in the ENROUTE Transcarotid NPS inline filter during a transcarotid stenting procedure.
- Conditions
- Carotid Stenosis, Carotid Artery Diseases, Carotid Atherosclerosis, Carotid Artery Plaque
- Trial name
- DW-MRI OUS (NCT03985774)
- Testing
- Transcarotid revascularization
- Where
- 3 sites in Belgium, Germany and 1 more
- Volunteers
- 31 people
- Sponsor
- Silk Road Medical
Aneurysm Cerebral, Bifurcation
LUMENS-1 Canada Early Feasibility Study Clinical Investigation Plan
The primary objective of this clinical investigation is to evaluate the early safety and feasibility of the LuSeed Aneurysm Embolization System for treating unruptured intracranial aneurysms (IA).
- Conditions
- Aneurysm Cerebral, Bifurcation, Unruptured Intracranial Aneurysm, Saccular Aneurysm
- Trial name
- NCT07259018
- Testing
- LuSeed Aneurysm Embolization System
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- LuSeed Vascular LTD.
Hemorrhagic Stroke, Ischemic Stroke
Early Feasibility Study of the SENSE Device
A single site, study of the SENSE device in up to 20 study subjects, (five healthy controls and five each with ICH, AIS with LVO and AIS without LVO) in whom SENSE can be applied within 24 hours of stroke symptom onset.
- Trial name
- NCT03827720
- Testing
- SENSE Device
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sense Diagnostics, LLC
Prevention & Control
Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
The primary objectives of this study are: To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction…
- Trial name
- COMPASS (NCT01776424)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Aspirin, Pantoprazole
- Where
- 565 sites in United States, Argentina and 31 more
- Volunteers
- 27,395 people
- Sponsor
- Bayer
Stroke
PROTECTED TAVR: Stroke PROTECTion With SEntinel During Transcatheter Aortic Valve Replacement
To demonstrate that use of the Sentinel® Cerebral Protection System significantly reduces the risk of peri-procedural stroke (≤72 hours) after transcatheter aortic valve replacement (TAVR).
- Trial name
- PROTECTED TAVR (NCT04149535)
- Testing
- Sentinel® Cerebral Protection System
- Where
- 57 sites in United States, Australia and 4 more
- Volunteers
- 3,000 people
- Sponsor
- Boston Scientific Corporation
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function.
- Trial name
- NCT06383390
- Testing
- Retatrutide
- Where
- 742 sites in United States, Argentina and 25 more
- Volunteers
- 10,000 people
- Sponsor
- Eli Lilly and Company
Intracerebral Hemorrhage, Cerebral Hemorrhage
MIECH: The Minimally Invasive Endoscopic Surgery With the Axonpen System for Spontaneous Intracerebral Hemorrhage
The primary objective of this trial is to provide preliminary safety data of minimally invasive endoscopic surgery using the Axonpen™ system for spontaneous intracerebral hemorrhage (ICH).
- Conditions
- Intracerebral Hemorrhage, Cerebral Hemorrhage, Intracranial Hemorrhage, Basal Ganglia Hemorrhage
- Trial name
- NCT04839770
- Testing
- Axonpen system
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- Clearmind Biomedical Inc.
Intracranial Aneurysm
Coil Assisted Flow Diversion Safety and Performance Study
Cerus Endovascular is sponsoring a prospective, single arm, multi-center study to document the safety and performance of Neqstent in adjunctive therapy.
- Trial name
- CAFI (NCT04187573)
- Testing
- Neqstent
- Where
- 7 sites in Austria, Canada and 3 more
- Volunteers
- 38 people
- Sponsor
- Cerus Endovascular, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.